NCT05411614 Hybrid Ablation of Atrial Fibrillation in Heart Failure
| NCT ID | NCT05411614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. George's Hospital, London |
| Condition | Persistent Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2022-06-25 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2022-06-25 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Persistent or Long-standing Persistent AF * Dilated left atrium (at least moderately dilated) * Suitable for either procedure * LVEF \< 50% Exclusion Criteria: * Not yet optimised from a medical or lifestyle perspective for AF or heart failure * Unable to provide written consent * Previous open-heart surgery * Active infection, oesophageal ulcer stricture or oesophageal varices * Prior catheter ablation of atrial fibrillation (prior ablation for atrial flutter / supraventricular tachycardia or ventricular arrhythmia acceptable) * Contraindication to anticoagulation, or active thrombus in the left atrium despite therapeutic anticoagulation * Severe valvular heart disease * Unstable coronary artery disease * Uncontrolled ventricular arrhythmia * Heart attack or stroke within the last 90 days * Pregnant, breastfeeding, or women of childbearing age who plan to get pregnant within six months * Severe concomitant condition or presence of an implanted device that would preclude the patient from undergoing trial procedures
Contact & Investigator
Riyaz A Kaba
PRINCIPAL INVESTIGATOR
St Georges Hospital NHS Trust
Frequently Asked Questions
Who can join the NCT05411614 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Persistent Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05411614 currently recruiting?
Yes, NCT05411614 is actively recruiting participants. Contact the research team at rkaba@sgul.ac.uk for enrollment information.
Where is the NCT05411614 trial being conducted?
This trial is being conducted at Chertsey, United Kingdom, Epsom, United Kingdom, London, United Kingdom, London, United Kingdom and 3 additional locations.
Who is sponsoring the NCT05411614 clinical trial?
NCT05411614 is sponsored by St. George's Hospital, London. The principal investigator is Riyaz A Kaba at St Georges Hospital NHS Trust. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.